<DOC>
	<DOCNO>NCT01416324</DOCNO>
	<brief_summary>The purpose study look safety tolerability increase single dos GSK2330672 healthy volunteer .</brief_summary>
	<brief_title>First Time Human Study Using GSK2330672</brief_title>
	<detailed_description>This single blind , randomize , placebo-controlled , dose escalating , crossover , first time human study examine safety , tolerability , pharmacokinetic pharmacodynamic parameter GSK233672 . Single blind indicate subject investigator blind treatment GSK study team could unblinded ongoing review interim safety data require dose escalation . Subjects participate 4 dose period . Subjects enter clinic prior dinner time even Day -1 period remain residence morning Day 3 . Barring safety tolerability concern , subject release time provide least 1 bowel movement dose clinic . Subjects return next schedule dosing period . This process repeat dosing period . Subjects return approximately 1 week check last dosing period follow visit . Subjects receive standardize meal meet specific criterion start dinner Day-1 continue Day 1 . Standard meal provide remainder stay clinic . After overnight fast , subject take study drug morning Day 1 . Dosing follow breakfast frequent blood sample assess pharmacokinetic pharmacodynamic parameter . Scheduled assessment heart rate , blood pressure , respiratory rate , ECGs , clinical laboratory obtain monitor subject safety . Subjects connect cardiac telemetry monitor periodically undergo spirometry test ventilation parameter . Stool form frequency bowel movement record . All fecal sample collect participant 48 hour dose study drug , least 1 bowel movement dosing , whichever occur first .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>healthy volunteer 1860 yr age subject age 50 : negative fecal occult blood test within 3 month prior expect start dose , normal result sigmoidoscopy colonoscopy within 5 yrs prior dose . female , must nonchildbearing potential pregnant breastfeeding female positive HIV positive Hep B , Hep C within 3 month screen positive drug abuse screen triglyceride &gt; 250 mg/dL current chronic history liver disease gastrointestinal gastrointestinal related condition could affect fat bile acid reabsorption pancreatitis colon cancer 1st degree relative colon cancer abnormal lung function test inability perform lung function test unwilling abstain smoking , alcohol , caffeine , illicit drug direct site staff exposure 4 new chemical entity 12 month prior first dose day . participation study would result donation approximately 550mL blood 56day period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>pharmacodynamics</keyword>
	<keyword>first time human</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>